Liposomal Sustained-Release Delivery Systems for Intravenous Injection. IV. : Antitumor Activity of Newly Synthesized Lipophilic 1-β-D-Arabinofuranosylcytosine Prodrug-Bearing Liposomes

スポンサーリンク

概要

• 論文の詳細を見る

• A lipophilic prodrug of 1-β-D-arabinofuranosylcytosine (Ara-C), namely N^4-[N-(cholesteryl-oxycarbonyl)glycyl]-Ara-C (COCG-Ara-C), was synthesized and its antitumor activity in a liposome-entrapped form was studied. COCG-Ara-C showed an increaesd lipophilicity and almost complete entrapment in liposomes. COCG-Ara-C was hydrolyzed to the parent drug chemically, but the hydrolysis was accelerated in the presence of mouse, rat and human plasma. The in vitro cytoxicity of the prodrug against P 388 leukemia was approximately one-fifth that of Ara-C and four times that of N^4-behenoyl-Ara-C (BHAC). For in vivo antitumor activity tests, unilamellar vesicles composed of egg phosphatidylcholine (PC), egg sphingomyelin (SM) and COCG-Ara-C in a molar ratio of 7 : 3 : X (X=0-2.0) were prepared by the combination of controlled dialysis and sequential extrusion. The vesicle size ranged from 108±18 nm to 124±18 nm. In all the antitumor activity studies, chemotherapy was performed intravenously. The antitumor activity of COCG-Ara-C-bearing liposomes against intraperitoneally- or intravenously-inoculated mouse L 1210 leukemia was clearly superior to those of Ara-C and BHAC aqueous solutions. The efficacy of COCG-Ara-C against L 1210 leukemia was dependent upon the dosage form : regardless of implantation route, liposomal COCG-Ara-C showed a more potent activity than free COCG-Ara-C (aqueous solution). Prodrug-bearing liposomes also inhibited the growth of a human lung adenocarcinoma A 549 xenograft implanted under the renal capsule more efficiently than did Ara-C and BHAC aqueous solutions. These results suggest the potential usefulness of COCG-Ara-C-bearing liposomes in cancer chemotherapy.

• 社団法人日本薬学会の論文
• 1988-09-25

著者

• 藤崎 二朗

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 藤崎 二郎

  藤沢薬品工業探索研究所

• 藤崎 二郎

  藤沢薬品工業

• 徳永 雄二

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 岩佐 知明

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 沢居 清治

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 加賀山 彰

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 藤崎 二郎

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 加賀山 影

  Exploratory Research Laboratories, Fujisawa Pharmaceutical Company, Ltd.,

• 徳永 雄二

  Pharmaceutical Institute, Tohoku University

• 徳永 雄二

  藤沢薬品工業 開発第二研

• 沢居 清治

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 加賀山 彰

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

• 岩佐 知明

  Exploratory Research Laboratories Fujisawa Pharmaceutical Company Ltd.

関連論文

• Regional Capacities of Gastrointestinal Absorption and Lymphatic Transport for Lipid-Soluble Dyes in Rats
• Potential Absorption of Heparin from the Small Intestine and the Large Intestine in the Presence of Monoolein Mixed Micelles
• キット製剤の将来展望(E・薬剤学, 製剤学, 病院薬学)
• Liposomal Sustained-Release Delivary Systems for Instravenous Injection. V. : Biological Disposition of Liposome-Entrapped Lipophilic Prodrug of 1-β-D-Arabinofuranosylcytosine
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. IV. : Antitumor Activity of Newly Synthesized Lipophilic 1-β-D-Arabinofuranosylcytosine Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. III. : Antitumor Activity of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. II. : Design of Liposome Carriers and Blood Disposition of Lipophilic Mitomycin C Prodrug-Bearing Liposomes
• Liposomal Sustained-Release Delivery Systems for Intravenous Injection. I. : Physicochemical and Biological Properties of Newly Synthesized Lipophilic Derivatives of Mitomycin C
• INDIRECT ELECTROREDUCTIVE CYCLIZATION FOR SYNTHESES OF KEY INTERMEDIATES OF SEVERAL INDOLE AND IPECAC ALKALOIDS
• Effect of Some Ionic and Nonionic Surfactants on the Intramuscular Absorption of Isonicotinamide
• O-66 セファメジンαノンバイアルキットの製剤設計 (2) : 製剤特性と機能性評価
• O-65 セファメジンαノンバイアルキットの製剤設計 (1) : 設計コンセプトと有用性評価
• 放出開始時間制御型経口投与システム (TES) の設計
• Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). III. Relation between Lag Time and Membrane
• セファメジンαノンバイアルキットの容器設計と品質保証
• Development of a Novel Drug Release System, Time-Controlled Explosion System (TES). II. Design of Multiparticulate TES and in Vitro Drug Release Properties
• Biopharmaceutical Study of the Hepato-biliary Transport of Drugs. IV. Development of the Method to Investigate the Process of the Active Secretion of Drugs from the Hepatocytes into the Bile Canaliculi and Its Application to the Biliary Excretion of Organ

もっと見る 閉じる

スポンサーリンク